Halozyme (HALO) Director Bernadette Connaughton Sells Shares

What Happened Bernadette Connaughton, a director of Halozyme Therapeutics (HALO), reported the sale of 1,626 shares on August 10, 2026 at $102.80 per share, for proceeds of $167,153. The transaction is reported as an open-market or private sale and is a disposal of stock (sale), which is typically considered routine rather than an explicit bullish signal.

Key Details

• Transaction date and price: Aug 10, 2026 — 1,626 shares sold at $102.80 each.
• Total proceeds: $167,153.
• Filing date: Aug 11, 2026 (timely relative to the Aug 10 transaction).
• Shares owned after transaction: Not specified in the provided excerpt of the filing — check the full Form 4 for post-sale holdings.
• Footnote: Sale was made pursuant to a written Rule 10b5-1 trading plan adopted by the reporting person on May 29, 2025 (per footnote F1).

Context Sales executed under a 10b5-1 plan are pre-arranged and can be used to avoid allegations of trading on nonpublic information; they are common for directors and executives. For retail investors, purchases typically carry more weight as a potential positive signal; routine, plan-driven sales like this are less informative about management’s view of the company’s prospects.